SAN DIEGO—In one presentation at Plenary Session 3, ACR Convergence 2023, Beth Wallace, MD, MSc, a staff physician at the VA Ann Arbor Healthcare System, Michigan, and an assistant professor at the University of Michigan, Ann Arbor, shared important data on the relationship between time-dependent cumulative glucocorticoid exposure and major adverse cardiovascular events (MACE) in a cohort of veterans with rheumatoid arthritis (RA).
After three years on the Committee for Research, Linda Hiraki, MD, ScD, has stepped into the role of chair. During her term, she aims to foster global connections to advance and expand the positive impact of rheumatology research.
Reimbursement has fallen below acquisition price for some biosimilar versions of infliximab, forcing practices and patients to make difficult decisions. The ACR is working to change this.
SAN DIEGO—During ACR Convergence 2023 in November, the ACR and the ARP honored a group of distinguished individuals who have made significant contributions to rheumatology research, education and patient care. This month, The Rheumatologist profiles the recipients of the ARP Merit Awards and ARP Master class, recognizing outstanding contributions to the field of rheumatology. The…
Community practice rheumatology may be a less-followed path within the specialty, and it brings with it certain challenges. However, it also offers rewards, such as autonomy and deep relationships with patients. The Rheumatologist recently interviewed three community practice rheumatologists from around the U.S. to find out about their approaches to patient management, staffing and other…
Researchers and physician-scientists often need practical advice for getting their work published. Here are insights into how to select an appropriate publication, manage co-author relationships and more from a panel of experts in both rheumatology and publishing.
A study found the continuation of tumor necrosis factor inhibitor (TNFi) treatment in patients with chronic rheumatic inflammatory diseases after pregnancy diagnosis was not associated with worse outcomes than those who discontinued treatment with TNFi’s.
In late October, the FDA approved the first biosimilar to ustekinumab to treat patients with psoriasis, psoriatic arthritis and other conditions. Ustekinumab-auub is expected to be available in the U.S. by 2025.
In 1937, the Turkish physician Hulusi Behçet described a number of patients with relapsing aphthous ulcers in the mouth and over the genitalia, as well as hypopyon iritis. Since that time, the eponymous condition, known as Behçet’s disease, has been recognized as a multisystem vasculitis that can present with myriad other signs and symptoms. Although…
I couldn’t help but roll my eyes. I was at a mandatory “training session” on patient communication for all clinicians at my institution. There, I was being coached on how to properly talk to patients. In theory, this isn’t a bad thing—we all need more education on how to facilitate inclusive and equitable conversations with…